QuickView for TNRC13;jsessionid=3D765BD25ABDC6EF1EDE0A75B9F1BD6C;jsessionid=A8AB09FA390A3AE4E0D1D6F38BF237B8;jsessionid=51586F57457820B19218871CCD1B1B0A;jsessionid=1378266A38B81A4711AC8DCC93F77B7F;jsessionid=73AC8971AD1AC6EB5D00E04011873BA7;jsessionid=F0B006071256602CB3F288DAD63A4DCE;jsessionid=084D8DE08BEC3C5A128D741EAF97F4D5;jsessionid=B3231D217D739F841D1CB1A505D89A39;jsessionid=855FC4CC528F2D6F12469C4170E9DEC4;jsessionid=4F75E3DEB94759DB2C11CF203FC8DC0D;jsessionid=9AC031618DA1E57B15C4C9DBC47AD953 (gene)

1. Ataxin-2 sequesters Raptor into aggregates and impairs cellular mTORC1 signaling.
2. ATXN2 is a target of N-terminal proteolysis.
3. A Case of Coexistent Spinocerebellar Ataxia Type 2 and Primary Progressive Multiple Sclerosis-Coinci…
4. ATXN2 intermediate expansions in amyotrophic lateral sclerosis.
5. TDP-43 impairs sleep in Drosophila through Ataxin-2-dependent metabolic disturbance.

There were no clinical trials for TNRC13;jsessionid=3D765BD25ABDC6EF1EDE0A75B9F1BD6C;jsessionid=A8AB09FA390A3AE4E0D1D6F38BF237B8;jsessionid=51586F57457820B19218871CCD1B1B0A;jsessionid=1378266A38B81A4711AC8DCC93F77B7F;jsessionid=73AC8971AD1AC6EB5D00E04011873BA7;jsessionid=F0B006071256602CB3F288DAD63A4DCE;jsessionid=084D8DE08BEC3C5A128D741EAF97F4D5;jsessionid=B3231D217D739F841D1CB1A505D89A39;jsessionid=855FC4CC528F2D6F12469C4170E9DEC4;jsessionid=4F75E3DEB94759DB2C11CF203FC8DC0D;jsessionid=9AC031618DA1E57B15C4C9DBC47AD953